Why India

India's clinical trial ecosystem has undergone a dramatic transformation. Strengthened regulations, a vast and diverse patient population, world-class medical infrastructure, and significant cost advantages have positioned India as the destination of choice for global pharmaceutical and biotech sponsors. As your CRO partner, Zetalix ensures you capture every advantage India offers — without compromising quality, compliance, or timelines.

India's population of 1.4 billion spans every ethnic, genetic, and demographic group — providing access to patient populations increasingly difficult to recruit in Western markets.

• Treatment-Naïve Populations — A large proportion of Indian patients are treatment-naïve for many chronic conditions, reducing confounding variables and enabling cleaner efficacy signals.
• High Disease Burden — Significant patient pools for oncology, cardiovascular disease, diabetes, CNS disorders, infectious diseases (tuberculosis, hepatitis, tropical diseases), and rare diseases.
• Rapid Enrollment — India's dense urban centers and established investigator networks enable recruitment velocities 2–5× faster than the US or EU for many indications.
• Genetic Diversity — India's diverse genetic landscape supports pharmacogenomics research and generates data relevant to multiple global populations.

Clinical trials in India offer substantial savings without compromising data quality or regulatory rigor.

Potential Savings as compared to US/EU markets

• Investigator grants & site costs: 50–65% lower
• Clinical monitoring (CRA costs): 45–55% lower
• Patient recruitment & retention: 40–60% lower
• Data management & biostatistics: 50–60% lower
• Regulatory & medical writing: 40–50% lower
• Laboratory & diagnostic services: 55–70% lower

These savings are structural — driven by India's favorable labor economics, healthcare infrastructure costs, and purchasing power — not by any reduction in quality or regulatory standards.

• New Drugs and Clinical Trials Rules (2019) — Defined timelines for regulatory review (30–90 days), academic clinical trial provisions, compensation frameworks, and clear guidelines for biologics, biosimilars, and medical devices.
• CDSCO Digitization — SUGAM portal provides online submission, tracking, and approval management with improved transparency.
• Ethics Committee Registration — Mandatory registration and accreditation under CDSCO ensures consistent ethical review nationwide.
• Pharmacovigilance Programme of India (PvPI) — 350+ Adverse Drug Reaction Monitoring Centres (AMCs) across the country.
• Data Integrity & GCP Compliance — India is an ICH observer nation with increasing alignment to ICH E6(R2) GCP guidelines, ensuring globally accepted data.

• NABL & NABH Accredited Facilities — Leading hospitals and labs hold national (NABL/NABH) and international (CAP, JCI) accreditations.
• Dedicated CRU/Phase I Units — World-class Clinical Research Units for early-phase studies with 24/7 medical supervision.
• Diagnostic & Bioanalytical Labs — GLP-compliant and WHO-prequalified labs for PK/PD, immunogenicity, and biomarker analysis.
• Medical Talent — India produces 80,000+ medical graduates and 30,000+ postgraduates annually — the largest pipeline of trained clinical investigators globally.

• India's time zone (IST, UTC+5:30) bridges US and EU business hours — enabling near-continuous project communication.
• English is the primary language of medical education, regulatory documentation, and clinical research operations — eliminating translation barriers.

• 3rd largest pharmaceutical industry globally by volume
• 4th globally in clinical trial registrations (CTRI)
• Member of the International Council for Harmonisation (ICH) as a regulatory observer
• WHO Prequalification — Multiple Indian manufacturing and laboratory facilities
• Signatory to Mutual Recognition Agreements (MRAs) with multiple regulatory authorities